(Q37055989)

18 August 2017

1 reference

title

Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma (English)

1 reference

18 August 2017

Jon J Hiles

1

1 reference

18 August 2017

Jill M Kolesar

series ordinal

2

1 reference

18 August 2017

publication date

1 January 2008

1 reference

American Journal of Health-System Pharmacy

18 August 2017

published in

1 reference

18 August 2017

volume

65

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

123-131

1 reference

18 August 2017

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060661

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060661

Renal cancer: molecular mechanisms and newer therapeutic options

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060661

Von Hippel-Lindau disease: a genetic study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060661

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060661

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060661

Receptor tyrosine kinases as targets for anticancer drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060661

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060661

Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060661

Sunitinib in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060661

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060661

Sorafenib in advanced clear-cell renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060661

Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060661

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060661

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060661

The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060661

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060661

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060661

Randomized discontinuation trials: Utility and efficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060661

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060661

Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060661

Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP060661

31 March 2020

Identifiers

DOI

10.2146/AJHP060661

1 reference

release_royoav4skzh5pnftlecsemoc4i

18 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/royoav4skzh5pnftlecsemoc4i

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference